|
J Biol Chem, Vol. 274, Issue 48, 34361-34368, November 26, 1999
Soluble Collagen VI Drives Serum-starved Fibroblasts through
S Phase and Prevents Apoptosis via Down-regulation of Bax*
Martin
Rühl ,
Ergün
Sahin ,
Manfred
Johannsen,
Rajan
Somasundaram,
Dirk
Manski,
Ernst Otto
Riecken, and
Detlef
Schuppan§¶
From the Department of Medicine I, Klinikum B. Franklin, Free
University of Berlin, Hindenburgdamm 30, 12200 Berlin and the
§ Department of Medicine I, University of
Erlangen-Nuernberg, Krankenhausstraße 12,
91054 Erlangen, Germany
 |
ABSTRACT |
We previously showed that soluble,
pepsin-solubilized collagen VI increases de novo DNA
synthesis in serum-starved HT1080 and 3T3 fibroblasts up to 100-fold
compared with soluble collagen I, reaching 80% of the stimulation
caused by 10% fetal calf serum. Here we show that collagen VI also
inhibits apoptotic cell death in serum-starved cells as evidenced by
morphological criteria, DNA laddering, complementary apoptosis assays
(terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling,
enzyme-linked immunosorbent assay, and fluorescence-activated cell
sorting), and quantification of apoptosis-regulating proteins. In the
presence of starving medium alone or collagen I, the proapoptotic Bax
was up-regulated 2-2.5-fold, compared with soluble collagen VI and
fetal calf serum, whereas levels of the antiapoptotic Bcl-2 protein
remained unaffected. In accordance with its potent stimulation of DNA
synthesis, soluble collagen VI carries serum-starved HT1080 and Balb
3T3 fibroblasts through G2 as shown by
fluorescence-activated cell sorting analysis, whereas cells exposed to
medium and collagen I where arrested at G1-S. This was
accompanied by a 2-3-fold increase in cyclin A, B, and D1 protein
expression. Collagen VI-induced inhibition of apoptotic cell death may
be operative during embryogenesis, wound healing, and fibrosis when
elevated tissue and blood levels of collagen VI are observed, thus
initiating a feedback loop of mesenchymal cell activation and proliferation.
 |
INTRODUCTION |
Apoptosis or programmed cell death is a distinct form of active
self-destruction. It is an important mechanism by which cells can be
eliminated from the organism, e.g. during tissue remodeling, embryogenesis, and immune elimination. Apoptosis is characterized by
typical morphological changes and triggered by biochemically defined
events (1). Morphologically, apoptotic cells are characterized by a
reduction in cell size, chromatin condensation, and membrane blebbing.
DNA fragmentation into multiples of 180 base pairs is regarded as the
hallmark of apoptosis, but degradation into larger DNA fragments has
also been described (2). Intracellular effectors of apoptosis are the
caspases, enzymes that degrade key structural and functional molecules
of the cell, such as nuclear lamins, cytoskeletal proteins, protein
kinases, and DNA repair enzymes (3). The Bcl-2 family of proteins plays
an important role in the regulation of apoptosis upstream of caspases.
Their antiapoptotic members close and their proapoptotic members open
mitochondrial membrane pores and thus regulate the release of
cytochrome C into the cytosol. Cytochrome c can then
activate procaspase 9 via formation of a complex with Apaf-1 (4). Bcl-2
family proteins function as homo- and heterodimers with the ratio of
death promoters to death suppressors presumably determining if a cell
enters the apoptotic pathway (5).
Apoptosis depends on signaling processes that derive from extracellular
or intracellular events. The tumor suppressor gene p53, regarded as
"guardian of the genome," is an example of intracellular regulation, because it is up-regulated in response to DNA damage and,
in turn, can slow cell cycle progression and/or promote apoptosis by
inducing the expression of the Bcl-2 family member Bax (6). Extracellularly, death factors such as tumor necrosis factor and Fas
ligand, by binding to their receptors, trigger a caspase cascade via
adaptor proteins (7). Other extracellular factors (e.g. interleukin-2 and -3 as well as nerve growth factor and insulin-like growth factor-1) provide survival rather than death signals for specialized cells (8).
Whereas much is known about regulation of apoptosis by growth factors,
cytokines, and hormones, the role of the extracellular matrix
(ECM)1 in regulating
apoptosis, although well recognized, is yet little understood (9, 10).
The most common approach to study the effect of ECM on apoptosis is to
plate cells on precoated ECM components (11). Using this approach, many
investigators have demonstrated that integrin-mediated adhesion and
spreading on ECM molecules is necessary for the survival of many cell
lines. Adhesion-dependent cells that are deprived of
anchorage die by an apoptotic mechanism called anoikis (12, 13). The
basement membrane has been shown to prevent apoptosis through
1-integrin signaling (14), and several distinct ECM
molecules such as fibronectin or collagens have been found to
facilitate survival through integrin-mediated signal transduction
pathways (15).
Collagen VI (CVI) is a large, multidomain ECM protein composed of a
triple-helix of the chains 1, 2, and
3, which, via tetramerization and end-to-end
association, assemble into a microfibrillar network in vivo
and in vitro (16). Its pattern of distribution and its
unique structure and expression compared with other ECM molecules
indicate that CVI might fulfill specialized tasks in tissue
organization and cell functioning (17-19). In this line, CVI interacts
with various other matrix components including hyaluronic acid (20),
syndecan (21), decorin (22), von Willebrand factor (23), and collagens,
types I, IV and XIV (19, 24). CVI has been shown to be highly expressed
around mesenchymal cells during development of liver (17) and eyes
(25), suggesting a role in cellular differentiation and survival (26).
In this line, strong expression of CVI has been reported around
malignant tumors like melanoma and glioma, which show more invasive
behavior than those not expressing CVI (27, 28). Native, triple-helical CVI as well as its single chains promote cell attachment, spreading, and proliferation through at least partially integrin-independent mechanisms (29, 30).
Here we describe the unique effect of soluble CVI, in the
absence of growth factors, to promote cell survival through
down-regulation of the proapoptotic Bax protein. Furthermore, CVI sets
the stage for cell cycle progression by up-regulating cyclins A, B, and D1.
 |
EXPERIMENTAL PROCEDURES |
If not stated otherwise, all reagents were obtained from Sigma
and were of the highest purity grade available.
Collagen Isolation--
Human collagen I (CI) and CVI were
isolated from human placentas by pepsin digestion, fractional salt
precipitation in acidic and neutral buffers, ion exchange, and
molecular sieve chromatography as described previously (30). All
preparations were tested for purity by SDS-PAGE and amino acid analysis
after hydrolysis in 6 N HCl under nitrogen for 24 h at
110 °C. Purified collagens were lyophilized and redissolved in 0.15 or 0.5 M acetic acid before use. Growth factor
contamination of CVI was excluded by pepsin digestion, molecular sieve
chromatography with a cut-off of 100 kDa in a buffer containing 6 M guanidine, and the use of neutralizing antibodies against
fibroblast growth factor, epidermal growth factor, PDGF AB, and
transforming growth factor- as described previously (30).
Cell Culture--
Balb 3T3 cells (mouse fibroblasts, ATCC
CCL-163) and HT1080 cells (human fibrosarcoma cells, ATCC CCL-121) were
cultured in 80-cm2 flasks using Dulbecco's modified
Eagle's medium with high glucose (4.5 g/liter) and
L-alanyl-L-glutamine (0.862 g/liter; Life
Technologies, Inc., Eggenstein, Germany) supplemented with penicillin
(107 units/liter), streptomycin (10 mg/liter), ascorbic acid (50 mg/liter), and 10% fetal calf serum (FCS) (Biochrom, Berlin, Germany)
under standardized conditions (37 °C, 8% CO2) in a
humidified atmosphere. Cells were then serum-starved for 24 h,
with no FCS (starving medium), followed by dissociation with 500 µl
of 0.05% trypsin-EDTA (Biochrom) and neutralization with 30 ml of
starving medium containing 1 g/liter soybean trypsin inhibitor and 1 g/liter ovalbumin. Alternatively, cells were scraped carefully with a
cell scraper (Costar, Cambridge, MA) to exclude any potential effect of
trypsin. After centrifugation at 800 × g for 10 min,
cells were washed twice with 20 ml of PBS (without Ca2+ and
Mg2+; Biochrom), resuspended in starving medium, and plated
at a density of 1.5-2 × 106 in 1.7 ml of starving
medium, followed by treatment with starving medium alone, 100 µl of
CI (20 mg/liter), 100 µl of CVI (20 mg/liter), or 10% FCS in
six-well plates (NUNC, Wiesbaden, Germany).
For experiments on defined adhesive or antiadhesive surfaces, one
million cells were seeded into six-well-plates (NUNC) coated either
with 3.1 mg/cm2 poly(2-hydroxyethylmethacrylate)
(poly-HEMA) in 95% ethanol or with 1% BSA in sterile PBS as
nonadhesive surfaces (30, 31) or with 60 µg/2 ml of CI or CVI
overnight at 4 °C. These saturating concentrations of the coating
substances were determined in pilot studies. Wells were washed three
times with 2 ml of PBS/Tween 0.05% at room temperature, followed by a
final wash with plain PBS. In integrin-blocking experiments freshly set
cells were incubated with anti 1-integrin antibody P4C10
(1:1000; Biomol, Hamburg, Germany), followed by immediate treatment
with solubilized collagens. After 24 h, cells were subjected to
FACS analysis.
Morphology--
24 h after plating and treatment, cells were
photographed using a Zeiss phase contrast microscope at a 1:40
magnification and Kodak Ektachrome 64 film.
Terminal Deoxynucleotidyl Transferase-mediated dUTP Nick End
Labeling--
24 h after plating and the addition of collagens or FCS,
cells were harvested by trypsinization or scraping, suspended in starving medium containing trypsin inhibitor (100 mg/liter),
centrifuged for 10 min at 800 × g, adjusted to the
same cell number, washed twice with 10 ml of 1% BSA in PBS, and
resuspended in 1 ml of PBS/BSA. Then cells were transferred to 1.5-ml
Eppendorf tubes and fixed in 4% paraformaldehyde for 30 min at room
temperature, centrifuged at 1,600 rpm for 10 min, washed twice with
PBS, and kept in 70% ethanol for storage at 20 °C or used
immediately. For further processing, ethanol was removed, and cells
were washed with PBS. Permeabilization was done by adding 500 µl of
PBS containing 0.1% Triton X-100 on ice for 2 min followed by two
washes with ice-cold PBS. 50 µl of reaction buffer containing
terminal deoxynucleotidyltransferase and fluoresceine-labeled dUTP were
used for in situ labeling of fragmented DNA (In
Situ Cell Death Detection; Roche Molecular Biochemicals). After
incubation at 37 °C for 1 h, cells were washed twice with 500 µl of PBS, cytospun onto microscope slides, and visualized under a
fluorescence microscope (Zeiss, Germany).
DNA Laddering--
After a 24-h treatment with medium, CI, CVI,
or 10% FCS, cells were trypsinized and adjusted to equal cell number
(1.5 × 106). The Apoptotic DNA Ladder Kit (Roche
Molecular Biochemicals) was used according to the manufacturer's
instructions, leading to isolation of oligonucleosomes. The isolated
DNA in each group was electrophoresed on a 1.5% agarose gel at 75 V
for 1.5 h, stained with ethidium bromide, and visualized via a UV
light source (302 nm). As a positive control, apoptotic DNA from HL60
cells (promyelocytic leukemia) was used.
Cell Death Detection ELISA--
4 × 105 cells
were plated in six-well plates and treated with starving medium or
medium plus CI, CVI, or FCS. After 6, 12, or 24 h, floating and
adherent cells were pooled and lysed with 500 µl of lysis buffer (1%
SDS, 10 mM Tris, pH 7.4) for 30 min at 4 °C. Lysed cells
were transferred to 1.5-ml Eppendorf tubes and centrifuged at 13,000 rpm for 20 min to separate low molecular weight DNA
(oligonucleosome-sized fragments derived from apoptotic cells) from
high molecular weight DNA (from viable cells). 400 µl of the
supernatant containing oligonucleosomes were carefully transferred to
another Eppendorf tube and diluted 1:5 with lysis buffer. A 100-µl
aliquot was used for the ELISA, which was performed according to the
manufacturer's instructions (Cell Death Detection ELISA; Roche
Molecular Biochemicals). In brief, antibodies against histones were
coated onto 96-well, 100-µl lysate samples containing oligonucleotides, and histones were added and incubated for 1 h.
After washing, the wells were incubated with anti-double strand DNA
antibody coupled to peroxidase for 1 h. After reaction with peroxidase substrate, absorbance was measured at 405 nm using an ELISA
reader. Background values (lysis buffer alone) were subtracted, and
results are shown as enrichment factor (enrichment factor = OD
(optical density) of the sample (apoptotic cells) divided by the OD of
the corresponding control (viable cells, FCS group)). A defined
positive control was prepared using a hypertonic buffer, containing 10 mM Tris, 400 mM NaCl, 5 mM
CaCl2, and 10 mM MgCl2, instead of
starving medium.
FACS Analysis--
1.5 × 106 freshly set cells
were treated with medium, CI, CVI, or FCS for 24 or 48 h as
described before. After trypsinization, cells were adjusted to same
cell number, washed with 10 ml of PBS, fixed in 70% ethanol for 30 min
at 20 °C, and suspended in 500 µl of PBS, containing RNase A
(250 mg/liter) for 30 min at 37 °C. Fixed cells were stained in a
final volume of 1 ml with propidium iodide (50 mg/liter) before being
subjected to FACS analysis as described (31).
Western Blot Analysis--
Trypsinized and washed cells were
centrifuged at 800 × g and lysed by the addition of
100 µl of lysis buffer (1% SDS, 10 mM Tris-HCl, pH 7.4).
DNA was sheared with an insulin syringe (Braun-Melsungen, Germany) by
up and down pipetting. Membrane fragments were removed by
centrifugation at 13,000 rpm for 10 min, and protein concentration in
each sample was determined using the BCA method (Pierce). Equivalent amounts of protein were removed, and volumes were adjusted to 20 µl.
After the addition of 2× sample buffer, the aliquots were boiled for 5 min and subjected to 12% SDS-PAGE.
After blocking for 1 h at room temperature in a buffer containing
10 mmol of Tris-HCl, pH 7.5, 100 mmol of NaCl, 0.1% Tween 20, and 3%
BSA, nitrocellulose membranes were incubated either with polyclonal
rabbit anti-human Bax (1:1000, sc-493; Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), monoclonal mouse anti-human Bcl-2 (1:250, B46620;
Transduction Laboratories, Lexington, KY), polyclonal rabbit anti-human
Bcl-2 (1:1000, sc783; Santa Cruz Biotechnology) or polyclonal rabbit
anti-human -actin (1:4000, A2066; Sigma), polyclonal anti-cyclin A
and anti-cylin B (1:250, sc-751 and sc-752, respectively; Santa Cruz
Biotechnology), and monoclonal anti-cyclin D1 (1:250, 14561a;
Pharmingen, Hamburg, Germany). The membranes were then washed three
times for 10 min in a buffer containing 10 mmol of Tris-HCl, pH 7.5, 100 mmol of NaCl, and 0.1% Tween 20 and incubated with anti-mouse-IgG
coupled to peroxidase (1:1000, A4416; Sigma) for 1 h at room
temperature. Reactive bands were detected with the ECL
chemiluminescence reagent (Amersham Pharmacia Biotech). After stripping
in 0.1 M glycin-HCl, pH 2, for 20 min at room temperature,
membranes were reprobed with appropriate primary and secondary
antibodies. Band intensities were analyzed by densitometry. Results are
shown as percentage of the control (10% FCS) after adjustment of band
intensity to that of -actin, which served as internal control.
 |
RESULTS |
Soluble Type VI Collagen Inhibits Apoptosis in Serum-starved
Fibroblasts--
Previous studies have shown that CVI strongly induces
cellular attachment and spreading (24, 29, 32). To test the hypothesis that soluble CVI inhibits programmed cell death, we induced apoptosis in transformed and nontransformed fibroblasts by serum withdrawal (33).
HT1080 and Balb 3T3 cells were synchronized over 24-48 h by culturing
in Dulbecco's modified Eagle's medium containing no FCS, trypsinized
thereafter, and seeded for the different assays as described under
"Experimental Procedures." After plating, cells were treated with
plain medium or 20 mg/liter pepsin-solubilized CI as negative controls,
with 10% FCS as positive control or with 20 mg/liter CVI. Initial
experiments included exposure of cells also to soluble collagens III,
IV, V, or XIV; to fibronectin; or to laminin, which were ineffective in
inhibiting apoptosis and of which CI was chosen as negative control for
all subsequent experiments. After an additional 24-48 h, cells were
harvested and subjected to several complementary assays to assess apoptosis.
The morphological features of apoptosis (i.e. cell shrinkage
and nuclear condensation) were evident with medium alone or CI, whereas
cells exposed to CVI or FCS remained well spread and viable after
24 h of treatment (Fig. 1).
Initially, cells in each group adhered and spread to an equal extent,
but, whereas cells exposed to medium or CI detached after 24 h,
cells treated with 10% FCS or CVI remained well spread for up to
96 h (data not shown).

View larger version (191K):
[in this window]
[in a new window]
|
Fig. 1.
Serum-starved HT1080 fibroblasts remain
viable upon exposure to soluble collagen VI. 2 × 106 HT1080 cells were plated on six-well plates in 1.7 ml
of starving medium, which was changed immediately to a medium
supplemented with 10% FCS, collagen I (20 mg/liter) or collagen VI (20 mg/liter) or changed to starving medium alone for 24 h. Sections
were photographed with a Zeiss phase-contrast microscope at a
magnification of 1:100. The morphological features for apoptotic cells
include cell shrinkage and nuclear condensation, as is evident in the
medium alone and the CI groups, whereas cells exposed to CVI and FCS
remain well spread and viable after 24 h of treatment. Similar
results were obtained for Balb 3T3 cells.
|
|
After 24 h the in situ terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling assay that highlights
apoptotic cells was clearly positive in 15-20% of cells treated
with medium alone or CI, contrasting with less than 2% positive cells
in the cultures treated with CVI or 10% FCS (Fig.
2).

View larger version (146K):
[in this window]
[in a new window]
|
Fig. 2.
Collagen VI prevents in situ
DNA fragmentation in HT1080 cells. 2 × 106
HT1080 cells were plated on six-well plates in 1.7 ml of starving
medium, which was changed after 2 h to a medium supplemented with
10% FCS, collagen I (20 mg/liter), collagen VI (20 mg/liter) or
changed to starving medium alone for 24 h. Cells were harvested by
trypsinization, adjusted to the same cell numbers, fixed in 4%
paraformaldehyde and 70% ethanol, permeabilized with 0.1% Triton
X-100, and 5'-end-labeled with fluoresceine-labeled dUTP. Cytospun
cells were visualized under a fluorescence microscope, with apoptotic
cells showing bright yellow, condensed nuclei in the groups treated
with medium alone or CI.
|
|
DNA laddering (degradation into multiples of 180-base pair-long
fragments) has been considered as one of the most characteristic signs
of apoptotic cell death (1). Serum-starved cells were plated and
treated as described before. When the isolated DNA was loaded onto a
2% agarose gel, the cells exposed to medium and CI exhibited typical
laddering, whereas no DNA fragmentation was visible in the presence of
CVI or 10% FCS (Fig. 3).

View larger version (90K):
[in this window]
[in a new window]
|
Fig. 3.
Prevention of DNA laddering in serum-starved
HT1080 cells by collagen VI. 2 × 106
serum-starved cells were plated and treated as described before
isolation of DNA. After a 24-h treatment as detailed in the legends to
Figs. 1 and 2, cellular DNA was extracted and subjected to agarose gel
electrophoresis. The cells exposed to plain medium and CI exhibited
typical laddering, whereas no fragmentation was visible in the presence
of CVI and 10% FCS. standard, DNA ladder standard (180-base
pair spacing); medium, starved cells treated with medium
alone; CI, collagen I-treated cells (20 mg/liter);
CVI, collagen VI-treated cells (20 mg/liter); 10%
FCS, cells maintained in 10% FCS; pos. control,
apoptotic HL60 cells (positive control). Shown is a representative
example of three independent experiments.
|
|
To quantify apoptotic cell death and to better delineate its time
course, we used the cell death detection ELISA (Fig.
4) and FACS analysis (Fig.
5). Both methods confirmed the
antiapoptotic effect of soluble CVI at 20 mg/liter (60 nmol/liter),
which was equipotent to 10% FCS. FACS analysis showed that after
24 h of treatment with CVI or 10% FCS, less than 1% of the cells
could be identified as apoptotic compared with 21 and 15% in the
medium and CI groups, respectively. After 48 h, the percentage of
apoptotic cells rose to 47% in the medium and CI group and increased
moderately in the CVI (12.5%) and 10% FCS (5.5%) groups,
respectively. Additionally, compared with plain medium or CI, a higher
number of cells in the CVI and 10% FCS groups were driven into the
G2 and S phase of the cell cycle, as evidenced by doubled
or increased DNA content (Fig. 5). After 48 h of treatment, 18 and
19%, respectively, of the cells treated with CVI or 10% FCS could be
detected in G2 compared with 3.8 and 5% in the medium and
CI groups.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 4.
Time course of apoptotic cell death in
serum-starved HT1080 cells (cell death detection ELISA). 4 × 105 cells were cultured in six-well plates and treated with
plain medium, CI or CVI (final concentration 20 mg/liter), or 10% FCS.
After 6, 12, or 24 h, cells were lysed, and low molecular weight
oligonucleosomal DNA (from viable cells) was detected by a sandwich
ELISA with antibodies against histones and DNA. Background OD values
(lysis buffer alone) were subtracted, and results are shown as
enrichment factor as proposed by the manufacturer (enrichment
factor = OD (optical density) of the sample (apoptotic cells)
divided by the OD of the corresponding control (viable cells, FCS
group)). Cells were exposed to the following. M, starving
medium; CI, collagen I (20 mg/liter); CVI,
collagen VI (20 mg/liter); FCS, 10% FCS. Apoptosis started
between 6 and 12 h after serum starvation, reaching an enrichment
factor of 9 and 5 after 24 h in the medium alone and CI-treated
group, respectively. Treatment with CVI as well as treatment with 10%
FCS resulted in strong inhibition of apoptosis during all treatment
periods (enrichment factor 1-2). Shown are means ± S.E. of three
experiments.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 5.
Cell cycle analysis of HT1080 cells exposed
to starving medium, collagens, or FCS. Serum-starved HT1080 cells
were treated with medium alone, CI, CVI (both at 20 mg/l), or 10% FCS
for 24 or 48 h. After fixation in 70% ethanol and RNase
digestion, cellular DNA was stained with propidium iodide and subjected
to FACS analysis. The integrated area of cellular DNA content was
calculated as percentage of cells in G0-G1,
G2-M, S phase transition, or apoptosis (hp,
hypoploid cells). Shown is a representative of three independent
experiments.
|
|
Soluble CVI Is More Effective than Immobilized CVI in Preventing
Apoptosis--
In order to compare the antiapoptotic effect of added
soluble CVI with that of immobilized CVI, we seeded HT1080 cells on the
nonadhesive substrates poly-HEMA (Fig.
6B) or BSA (Fig.
6C) or on plastic, CI, or CVI, followed by the addition of
soluble CI, CVI, plain medium, or FCS (Fig. 6A). After
24 h, propidium iodide-stained cells were subjected to FACS
analysis. Here, soluble CVI was twice as efficient in preventing
apoptosis as coated CVI and 4 times more efficient than coated or
soluble CI (Fig. 6A). These experiments again showed that
soluble CVI is almost as potent as 10% FCS in preventing apoptosis
with 8 and 6% apoptotic cells, respectively.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 6.
Cell survival on antiadhesive or adhesive
surfaces. 106 serum-starved HT1080 cells were seeded
into uncoated ( ) six-well plates or plates coated with collagens (CI
and CVI) (A), poly-HEMA (pHema) (B),
and 1% BSA in PBS (BSA) (C). D, cells
were added to uncoated wells 2 h after the addition of
1-integrin receptor blocking antibody P4C10. Wells were
then immediately treated with medium alone ( ), soluble CI
(sCI) or CVI (sCVI), or 10% FCS
(FCS). After 24 h, cells were subjected to FACS
analysis as shown in Fig. 5. The area under the
shoulder left of the peak that
represents the G0-G1 fraction of the FACS
histogram in D (hypopl, hypoploid cells) was
taken as the percentage of apoptotic cells. The results shown are
means ± S.E. or means of three or four independent
experiments.
|
|
CVI Prevents Apoptosis via a Partially Spreading and
1-Integrin-independent Mechanism--
Attachment and
spreading were decreased by coating the wells with the nonadhesive
substrata poly-HEMA (Fig. 6B) or BSA (Fig. 6C).
Since anchorage-dependent cells undergo apoptosis under
conditions that prevent attachment and spreading (14), we next
investigated whether the anti-apoptotic effect of type VI collagen
might be due to promoting attachment and spreading. Cells plated on
poly-HEMA showed no spreading in any treatment group, and 40% of cells
were apoptotic when treated with plain medium or CI after 24 h
compared with 20 and 10% in the CVI-treated and 10% FCS groups,
respectively. The survival-promoting effect of soluble CVI on cells
plated onto BSA was even more pronounced: less than 1% of the cells
died compared with 20-25% apoptotic cells treated with CI or plain
medium. These results suggest that spreading-independent mechanisms
contribute to the antiapoptotic effect of soluble CVI.
When 1-integrin function was blocked with monoclonal
antibody P4C10 shortly before the addition of CI or CVI, cell spreading was inhibited. Under these conditions, the ratios of apoptotic cells
versus cells in G1 were 3.0, 1.2, and 0.7 for
plain medium, collagen I, and collagen VI, respectively, compared with
complete suppression of apoptosis by FCS (Fig. 6D). This
indicates an important but not exclusive role of
1-integrins in antiapoptotic signals transduced by
CVI.
Proapoptotic Bax Is Down-regulated by Soluble CVI--
To study
whether soluble CVI may be regulating key proapoptotic or antiapoptotic
proteins, such as Bax and Bcl-2 (4), we determined the levels of these
two proteins by quantitative Western blot analysis. The ratio of
Bax/Bcl-2 is thought to be crucial for cell survival. Fig.
7 illustrates that in HT1080 cells,
relative to the internal standard -actin, Bcl-2 levels remained
unaltered upon treatment with CVI or 10% FCS compared with medium or
CI, whereas in Balb 3T3 cells, 10% FCS but not CVI caused a 3-fold up-regulation of Bcl-2 (data not shown). In contrast, CVI clearly down-regulated Bax 2-3-fold in both cell lines. This effect was comparable with the 3-fold down-regulation of Bax observed with 10%
FCS compared with medium alone or CI. Thus, in HT1080 cells, the
Bax/Bcl-2 ratio was decreased 3-fold upon CVI treatment, thus favoring
cell survival.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 7.
Expression of Bax and Bcl-2 protein in
collagen VI-treated HT1080 cells. HT1080 cells were treated with
medium alone, CI, CVI, or 10% FCS for 24 h. Cell lysates were
adjusted to equal protein contents, run on a 12% SDS-PAGE, and blotted
onto nitrocellulose, followed by sequential incubation with polyclonal
rabbit anti-human Bax, monoclonal mouse anti-human Bcl-2, or polyclonal
rabbit anti-human -actin. Membranes were developed with
anti-mouse-IgG coupled to peroxidase and detected with the ECL
chemiluminescence reagent. After stripping in acidic glycine buffer,
membranes were reprobed with appropriate primary and secondary
antibodies. Bands were analyzed by densitometry, and results are shown
as percentage of the 10% FCS-treated control, normalized to cellular
-actin content. M, starving medium; CI,
collagen I (20 mg/liter); CVI, collagen VI (20 mg/liter);
FCS, 10% FCS. B, ratio of Bax/Bcl-2 for HT1080
cells. Shown is a representative example of four independent
experiments.
|
|
Soluble CVI Induces Cell Cycle Progression through Up-regulation of
Cyclins A, B, and D1--
Cyclins A, D, and E have been reported to be
regulated by a coordinated stimulation of growth factors and ECM
molecules in adhesion-dependent cells (34). Induction of
cell cycle progression through up-regulation of specific cyclins by ECM
molecules alone has not been reported. Therefore, we analyzed the
expression of cyclins A, B, and D1 after the addition of various
stimuli including CVI. Expression of the
anchorage-dependent cyclin A is up-regulated during S
phase, and cyclin B controls cell cycle progression into G2
(35). Similarly, cyclin D1 controls entry into the G1-S
phase in many cell lines, including fibroblasts, but fails to do so in
the absence of ECM signaling (36). Fig. 8
shows that CVI alone up-regulated cyclins A, B, and D1 2-3-fold
compared with plain medium or CI, comparable with cells treated with
10% FCS. These results are in full agreement with our cell cycle
analysis by FACS scan, which showed that only in the presence of CVI or FCS had a significant percentage of cells progressed to G2
(Fig. 5).

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 8.
Expression of cyclins A, B, and D1 in
collagen VI-treated HT1080 cells. HT1080 cells were treated with
medium alone, CI, CVI, or 10% FCS for 24 h. Equal amounts of cell
lysate were run on 12% SDS-PAGE and blotted onto nitrocellulose, which
was incubated with antibodies to (a) cyclin D1,
(b) cyclin A, and (c) cyclin B followed by
stripping and reprobing with polyclonal rabbit anti-human -actin.
Membranes were developed with anti-mouse-IgG coupled to peroxidase and
detected with the ECL chemiluminescence reagent. After stripping in
acidic glycine buffer, membranes were reprobed with the appropriate
primary and secondary antibodies. Bands were analyzed by densitometry,
and results are shown as percentage of the 10% FCS-treated control,
normalized to cellular -actin content. M, starving
medium; CI, collagen I (20 mg/liter); CVI, collagen VI (20 mg/liter); FCS, 10% FCS. *, control cell lysate to test the
specificity of antibodies. Shown is a representative example of three
experiments.
|
|
 |
DISCUSSION |
Adhesion of cells to several ECM proteins can prevent
apoptosis under conditions of nutrient and growth factor
deficiency. A recent report showed that the soluble, ECM-derived
1-integrin ligand collagen I can rescue detached and
serum-starved neuronal cells from apoptosis (37). Here, by using
complementary methods, we could demonstrate that soluble,
contrary to immobilized, CVI prevents apoptosis in
serum-starved HT1080 and Balb 3T3 cells. The antiapoptotic effect of
CVI is comparable with that provided by 10% fetal calf serum and far
more potent than that contributed by single, classical growth factors
for mesenchymal cells. Furthermore, soluble CVI induced a 2-3-fold
down-regulation of the proapoptotic Bax, again comparable with 10%
FCS, whereas expression of Bcl-2 was unaffected. In line with our
previous observations of the strong activation of DNA-synthesis by
soluble CVI (30), its antiapoptotic effect was accompanied by a
2-3-fold up-regulation, compared with medium control, of cyclins A, B,
and D1, which are required for progression of the cell cycle from
G1 to G2. This up-regulation reached 70-80%
of cells cultured in 10% FCS.
When offered CVI as adhesive substrate, the viability of corneal cells
is enhanced 2-fold compared with a matrix of CI (26). While our data
support these findings for immobilized CVI, the soluble form of CVI,
compared with soluble collagen I, is even more potent in preventing
apoptosis in HT1080 and 3T3 cells.
One explanation for the more pronounced antiapoptotic effect of soluble
CVI may be the creation of a pericellular microfilamentous CVI network
due to in vitro polymerization (38) that resembles the
pericellular CVI matrix in vivo and increases interactions with the cellular CVI receptors. Such interactions can subject cells to
increased tension and are accompanied by enhanced spreading (39). The
degree of spreading has been shown to correlate with cell survival and
proliferation (40). Besides determining proliferation and apoptosis via
cell shape alterations, generation of tensile stress may alter
responsiveness to growth factors (41). Thus, fibroblasts that are
cultured in collagen matrices respond to PDGF signaling with DNA
synthesis, while the same cells fail to respond to the growth factor
when stress is relaxed in a collagen gel (41). However, when cells were
plated on nonadhesive surfaces, we observed no spreading after the
addition of soluble CVI, despite a potent antiapoptotic effect,
suggesting the existence of spreading-independent pathways of
CVI-induced signal transduction.
Whereas the integrins 2 1 and
1 1 are receptors for native, triple
helical CVI, and 5 1,
v 3, and
IIb 3 recognize denatured CVI, they all
promote cell migration and spreading after ligation of CVI (29). A
nonintegrin CVI receptor, the chondroitin sulfate proteoglycan NG2
(42-45), has been shown to colocalize with the PDGF receptor.
Interestingly, PDGF receptor signaling is disrupted by NG2
down-regulation, suggesting a cross-talk between CVI and PDGF receptors
(46, 47). In accordance with these findings and previous reports (26,
30), the effects of CVI on proliferation and apoptosis were not
solely dependent on 1-integrins, since integrin-blocking
antibodies only partially influenced CVI-induced proliferation or
apoptosis as shown in Fig. 6D, suggesting that NG2 could be
an important proliferation-inducing and antiapoptotic CVI receptor
(42-45).
Searching for proteins that are involved in the CVI-mediated prevention
of apoptosis, we studied the expression of antiapoptotic Bcl-2 and
proapoptotic Bax, the ratio of which determines the susceptibility to
programmed cell death in various cell types (48, 49). CVI suppressed
Bax up-regulation upon serum withdrawal to a similar degree as
treatment with 10% FCS. In addition to growth factors, ECM-receptor
interactions have been shown to alter the ratio of Bcl-2/Bax.
Accordingly, one previous study showed that engagement of the integrin
5 1 can promote survival of cells on
fibronectin by up-regulation of Bcl-2 expression (50). Since soluble
CVI leads to activation of the focal adhesion kinase (51), which has
been shown to play an important role in preventing apoptosis (52),
focal adhesion kinase could be a central mediator of the antiapoptotic
CVI signaling.
Mammalian cells express various cyclin-dependent kinases
that function at different stages of the cell cycle. Their function is
modulated by the cell cycle-dependent expression of four
distinct types of cyclins; in concert with cyclin-dependent
kinases 4 and 6, the D-type cyclins drive cell cycle progression
through the G1 phase, which is also promoted by the cyclin
E-cyclin-dependent kinase 2 complex, whereas the cyclin
A-cyclin-dependent kinase 2 complex carries the cells
through S-phase, and cyclin B-cyclin-dependent kinase 2 is responsible
for progression through G2/M. Growth factors and cell
anchorage jointly regulate transit through G1 in almost all
cell types, but the molecular basis for this combined requirement remains largely unknown (35). Here, we show that soluble CVI alone is
sufficient to drive cell cycle progression through up-regulation of
cyclins A, B, and D1, which explains the previously observed stimulation of DNA synthesis by CVI (30). Since the mitogen-activated protein kinase, extracellular signal-regulated kinase-2, a major second
messenger in mitogenesis, is activated 20-fold after exposure of HT1080
cells to CVI (51), the observed up-regulation of cyclin D1 might be
linked to mitogen-activated protein kinase activation (53). We
therefore hypothesize that CVI has intrinsic growth factor-like properties.
A prominent matrix of CVI is found around fibroblasts (16), neural
crest (32), and hematopoietic stem cells (20), suggesting a role of
this collagen for mesenchymal cell differentiation during development.
Increased expression of CVI is found in the ECM of melanomas or gliomas
(27, 28) or in chronic fibrotic conditions (54, 55). Thus, CVI-content
is increased 10-fold in fibrotic livers, and CVI serum levels are
highly elevated in adults and children with advanced renal and hepatic
fibrosis (55-57). Therefore, enhanced proteolysis and release of CVI
during continuous inflammation and matrix turnover could trigger
mesenchymal cell proliferation in an autocrine and paracrine manner.
Considering the potential of CVI to serve as a survival factor for
fibrogenic cells, novel strategies for antifibrotic treatment can be
envisaged. Thus, CVI receptor-recognizing peptides may specifically
target and antagonize activated myofibroblasts, which are the main
producers of excess ECM in fibrosis of the liver, kidneys, lungs, and
arteries. Recent in vivo experiments show that after
intravenous injection more than 50% of a cyclic peptide with
specificity for a CVI receptor (58) reaches activated hepatic stellate
cells, the major fibrogenic cells in liver (59).
 |
ACKNOWLEDGEMENTS |
We thank Renate Ackermann and Monika Schmid
for expert technical assistance and Dr. S. Rosewicz, K. Detjens, and M. Welser for support in FACS analysis.
 |
FOOTNOTES |
*
This project was funded by Sonderforschungsbereich 366 C5
and Deutsche Forschungsgemeinschaft Grant Schu 646/10-2. D.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Both authors contributed equally to this work.
¶
Recipient of a
Hermann-und-Lilly-Schilling-professorship. To whom correspondence
should be addressed: Med. Klinik I, Universität Erlangen-Nürnberg, Krankenhausstr. 12, 91054 Erlangen, Germany. Tel.: 49-91318533386; Fax: 49-91318536003; E-mail:
detlef.schuppan@med1.med.uni-erlangen.de.
 |
ABBREVIATIONS |
The abbreviations used are:
ECM, extracellular
matrix;
BSA, bovine serum albumin;
CI, collagen I;
CVI, collagen type
VI;
FACS, fluorescence-activated cell sorting;
FCS, fetal calf serum;
PAGE, polyacrylamide gel electrophoresis;
PBS, phosphate-buffered
saline;
poly-HEMA, poly(2-hydroxymethylmethacrylate);
PDGF, platelet-derived growth factor;
ELISA, enzyme-linked immunosorbent
assay.
 |
REFERENCES |
| 1.
|
Wyllie, A. H.
(1993)
Br. J. Cancer
67,
205-208[Medline]
[Order article via Infotrieve]
|
| 2.
|
Oberhammer, F.,
Wilson, J. W.,
Dive, C.,
Morris, I. D.,
Hickman, J. A.,
Wakeling, A. E.,
Walker, P. R.,
and Sikorska, M.
(1993)
EMBO J.
12,
3679-3684[Medline]
[Order article via Infotrieve]
|
| 3.
|
Thornberry, N. A.,
and Lazebnik, Y.
(1998)
Science
281,
1312-1316[Abstract/Free Full Text]
|
| 4.
|
Green, D.
(1998)
Cell
94,
695-690[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Kroemer, G.
(1997)
Nat. Med.
3,
614-620[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Marzo, I.,
Brenner, C.,
Zamzami, N.,
Jürgensmeier, J. M.,
Susin, S. A.,
Vieira, H. L.,
Prévost, M. C.,
Xie, Z.,
Matsuyama, S.,
Reed, J. C.,
and Kroemer, G.
(1998)
Science
281,
2027-2031[Abstract/Free Full Text]
|
| 7.
|
Ashkenazi, A.,
and Dixit, V. M.
(1998)
Science
281,
1305-1308[Abstract/Free Full Text]
|
| 8.
|
Gajewski, T.,
and Thompson, C. B.
(1996)
Cell
87,
589-592[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Boudreau, N.,
Werb, Z.,
and Bissell, M. J.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
3509-3513[Abstract/Free Full Text]
|
| 10.
|
Meredith, J.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
8856-8860[Abstract/Free Full Text]
|
| 11.
|
Roskelley, C. D.,
Srebrow, A.,
and Bissel, M. J.
(1995)
Curr. Opin. Cell Biol.
7,
736-747[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Frisch, S. M.,
and Francis, H.
(1994)
J. Cell Biol.
124,
619-626[Abstract/Free Full Text]
|
| 13.
|
Ruoslahti, E.,
and Reed, J. C.
(1994)
Cell
77,
477-478[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Meredith, J. E., Jr.,
Fazeli, B.,
and Schwartz, M. A.
(1993)
Mol. Biol. Cell
4,
953-961[Abstract]
|
| 15.
|
Aplin, A. E.,
Howe, A.,
Alahari, S. K.,
and Juliano, R. L.
(1998)
Pharmacol. Rev.
50,
197-263[Abstract/Free Full Text]
|
| 16.
|
Bruns, R. R.,
Press, W.,
Engvall, E.,
Timpl, R.,
and Gross, J.
(1986)
J. Cell Biol.
103,
393-404[Abstract/Free Full Text]
|
| 17.
|
Loreal, O.,
Clement, B.,
Schuppan, D.,
Rescan, P. Y.,
Rissel, M.,
and Guillouzo, A.
(1992)
Gastroenterology
102,
980-987[Medline]
[Order article via Infotrieve]
|
| 18.
|
Hatamochi, A.,
Aumailley, M.,
Mauch, C.,
Chu, M. L.,
Timpl, R.,
and Krieg, T.
(1989)
J. Biol. Chem.
264,
3494-3499[Abstract/Free Full Text]
|
| 19.
|
Kuo, H. J.,
Maslen, C. L.,
Keene, D. R.,
and Glanville, R. W.
(1997)
J. Biol. Chem.
272,
26522-26529[Abstract/Free Full Text]
|
| 20.
|
Kielty, C. M.,
Whittaker, S. P.,
Grant, M. E.,
and Shuttleworth, C. A.
(1992)
J. Cell Biol.
118,
979-990[Abstract/Free Full Text]
|
| 21.
|
Klein, G.,
Muller, C. A.,
Tillet, E.,
Chu, M. L.,
and Timpl, R.
(1995)
Blood
86,
1740-1748[Abstract/Free Full Text]
|
| 22.
|
Bidanset, D. J.,
Guidry, C.,
Rosenberg, L. C.,
Choi, H. U.,
Timpl, R.,
and Hook, M.
(1992)
J. Biol. Chem.
267,
5250-5256[Abstract/Free Full Text]
|
| 23.
|
Hoylaerts, M. F.,
Yamamoto, H.,
Nuyts, K.,
Vreys, I.,
Deckmyn, H.,
and Vermylen, J.
(1997)
Biochem. J.
324,
185-191
|
| 24.
|
Brown, J. C.,
Mann, K.,
Wiedemann, H.,
and Timpl, R.
(1993)
J. Cell Biol.
120,
557-567[Abstract/Free Full Text]
|
| 25.
|
Doane, K. J.,
Yang, G.,
and Birk, D. E.
(1992)
Exp. Cell Res.
200,
490-499[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Howell, S. J.,
and Doane, K. J.
(1998)
Exp. Cell Res.
241,
230-241[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Han, J.,
Daniel, J. C.,
and Pappas, G. D.
(1995)
Cancer Lett.
88,
127-132[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Daniels, K. J.,
Boldt, H. C.,
Martin, J. A.,
Gardner, L. M.,
Meyer, M.,
and Folberg, R.
(1996)
Lab. Invest.
75,
55-66[Medline]
[Order article via Infotrieve]
|
| 29.
|
Pfaff, M.,
Aumailley, M.,
Specks, U.,
Knolle, J.,
Zerwes, H. G.,
and Timpl, R.
(1993)
Exp. Cell Res.
206,
167-176[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Atkinson, J. C.,
Rühl, M.,
Becker, J.,
Ackermann, R.,
and Schuppan, D.
(1996)
Exp. Cell Res.
228,
283-291[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Ormerod, M. G.
(1998)
Leukemia
12,
1013-1025[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Perris, R.,
Kuo, H.-J.,
Glanville, R. W.,
Leibold, S.,
and Bronner-Fraser, M.
(1993)
Exp. Cell Res.
209,
103-117[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Kulkarni, G. V.,
and McCulloch, C. A. G.
(1994)
J. Cell Sci.
107,
1169-1179[Abstract]
|
| 34.
|
Elledge, S. J.
(1996)
Science
274,
1664-1671[Abstract/Free Full Text]
|
| 35.
|
Assoian, R. K.
(1997)
Cytokine Growth Factor Rev.
8,
165-170[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Zhu, X.,
Ohtsubo, M.,
Boehmer, R. M.,
Roberts, J. M.,
and Assoian, R. K.
(1996)
J. Cell Biol.
133,
391-403[Abstract/Free Full Text]
|
| 37.
|
Bozzo, C.,
Bellomo, G.,
Silengo, L.,
Tarone, G.,
and Altruda, F.
(1997)
Exp. Cell Res.
237,
326-337[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Colombatti, A.,
Mucignat, M. T.,
and Bonaldo, P.
(1995)
J. Biol. Chem.
270,
13105-13111[Abstract/Free Full Text]
|
| 39.
|
Chen, C. S.,
Mrksich, M.,
Huang, S.,
Whitesides, G. M.,
and Ingber, D. E.
(1997)
Science
276,
1425-1428[Abstract/Free Full Text]
|
| 40.
|
Ingber, D. E.,
and Folkman, J.
(1989)
J. Cell Biol.
109,
317-330[Abstract/Free Full Text]
|
| 41.
|
Lin, Y. C.,
and Grinnell, F.
(1993)
J. Cell Biol.
122,
663-672[Abstract/Free Full Text]
|
| 42.
|
Burg, M. A.,
Tillet, E.,
Timpl, R.,
and Stallcup, W. B.
(1996)
J. Biol. Chem.
271,
26110-26116[Abstract/Free Full Text]
|
| 43.
|
Burg, M. A.,
Nishiyama, A.,
and Stallcup, W. B.
(1997)
Exp. Cell Res.
235,
256-264
|
| 44.
|
Doane, K. J.,
Howell, S. J.,
and Birk, D. E.
(1998)
Invest. Ophatalmol. Vis. Sci.
39,
263-275[Abstract/Free Full Text]
|
| 45.
|
Stallcup, W. B.,
Dahlin, K.,
and Healy, P.
(1990)
J. Cell Biol.
111,
3177-3188[Abstract/Free Full Text]
|
| 46.
|
Nishiyama, A.,
Lin, X. H.,
Giese, N.,
Heldin, C. H.,
and Stallcup, W. B.
(1996)
J. Neurosci. Res.
43,
299-314[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Nishiyama, A.,
Lin, X. H.,
Giese, N.,
Heldin, C. H.,
and Stallcup, W. B.
(1996)
J. Neurosci. Res.
43,
315-330[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Oltvai, Z. N.,
Milliman, C. L.,
and Korsmeyer, S. J.
(1993)
Cell
74,
609-619[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
O'Reilly, L. A.,
Huang, D. C.,
and Strasser, A.
(1996)
EMBO J
15,
6979-6990[Medline]
[Order article via Infotrieve]
|
| 50.
|
Zhang, Z.,
Vuori, K.,
Reed, J. C.,
and Ruoslahti, E.
(1995)
Proc. Natl. Acad. Sci U. S. A.
92,
6161-6165[Abstract/Free Full Text]
|
| 51.
|
Rühl, M.,
Johannsen, M.,
Atkinson, J.,
Manski, D.,
Sahin, E.,
and Schuppan, D.
(1999)
Exp. Cell Res.
250,
548-557[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Hungerford, J. E.,
Compton, M. T.,
Matter, M. L.,
Hoffstrom, B. G.,
and Otey, C. A.
(1996)
J. Cell Biol.
135,
1383-1390[Abstract/Free Full Text]
|
| 53.
|
Lavoie, J. N.,
L'Allemain, G.,
Brunet, A.,
Müller, R.,
and Pouysségur, J.
(1996)
J. Biol. Chem.
271,
20608-20616[Abstract/Free Full Text]
|
| 54.
|
Nerlich, A. G.,
Schleicher, E. D.,
Wiest, I.,
Specks, U.,
and Timpl, R.
(1994)
Kidney Int.
45,
1648-1654[Medline]
[Order article via Infotrieve]
|
| 55.
|
Shahin, M.,
Schuppan, D.,
Waldherr, R.,
Risteli, J.,
Risteli, L.,
Savolainen, E. R.,
Oesterling, C.,
Abdel Rahman, H. M.,
el Sahly, A. M.,
Abdel Razek, S. M.,
and Seitz, H. K.
(1992)
Hepatology
15,
637-644[Medline]
[Order article via Infotrieve]
|
| 56.
|
Marder, K.,
Keller, F.,
and Schuppan, D.
(1995)
Clin. Nephrol.
44,
178-184[Medline]
[Order article via Infotrieve]
|
| 57.
|
Gerling, B.,
Becker, M.,
Staab, D.,
and Schuppan, D.
(1997)
N. Engl. J. Med.
336,
1611-1612[Free Full Text]
|
| 58.
|
Cardarelli, P. M.,
Yamagata, S.,
Taguchi, I,
Gorcsan, F.,
Chiang, S. L.,
and Lobl, T.
(1992)
J. Biol. Chem.
267,
23159-23162[Abstract/Free Full Text]
|
| 59.
|
Beljaars, L.,
Poelstra, K.,
Weert, B.,
Molema, G.,
Schuppan, D.,
and Meijer, D. K. F.
(1998)
Hepatology
28,
313A (abstr.)
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. Guillen-Ahlers, S. A. Buechler, M. A. Suckow, F. J. Castellino, and V. A. Ploplis
Sulindac treatment alters collagen and matrilysin expression in adenomas of ApcMin/+ mice
Carcinogenesis,
July 1, 2008;
29(7):
1421 - 1427.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Schnoor, P. Cullen, J. Lorkowski, K. Stolle, H. Robenek, D. Troyer, J. Rauterberg, and S. Lorkowski
Production of Type VI Collagen by Human Macrophages: A New Dimension in Macrophage Functional Heterogeneity
J. Immunol.,
April 15, 2008;
180(8):
5707 - 5719.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Chang, M. Zuka, P. Perez-Pinera, A. Astudillo, J. Mortimer, J. R. Berenson, and T. F. Deuel
Secretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment
PNAS,
June 26, 2007;
104(26):
10888 - 10893.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ruehl, U. Erben, D. Schuppan, C. Wagner, A. Zeller, C. Freise, H. Al-Hasani, M. Loesekann, M. Notter, B. M. Wittig, et al.
The Elongated First Fibronectin Type III Domain of Collagen XIV Is an Inducer of Quiescence and Differentiation in Fibroblasts and Preadipocytes
J. Biol. Chem.,
November 18, 2005;
280(46):
38537 - 38543.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A K Lampe and K M D Bushby
Collagen VI related muscle disorders
J. Med. Genet.,
September 1, 2005;
42(9):
673 - 685.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Celis, J. M. A. Moreira, T. Cabezon, P. Gromov, E. Friis, F. Rank, and I. Gromova
Identification of Extracellular and Intracellular Signaling Components of the Mammary Adipose Tissue and Its Interstitial Fluid in High Risk Breast Cancer Patients: Toward Dissecting The Molecular Circuitry of Epithelial-Adipocyte Stromal Cell Interactions
Mol. Cell. Proteomics,
April 1, 2005;
4(4):
492 - 522.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. H. Mnjoyan, R. Dutta, D. Zhang, B.-B. Teng, and K. Fujise
Paradoxical Upregulation of Tumor Suppressor Protein p53 in Serum-Stimulated Vascular Smooth Muscle Cells: A Novel Negative-Feedback Regulatory Mechanism
Circulation,
July 29, 2003;
108(4):
464 - 471.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. B. Stallcup and K. Dahlin-Huppe
Chondroitin sulfate and cytoplasmic domain-dependent membrane targeting of the NG2 proteoglycan promotes retraction fiber formation and cell polarization
J. Cell Sci.,
March 8, 2002;
114(12):
2315 - 2325.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|